Related references
Note: Only part of the references are listed.Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
Qiyan Zheng et al.
FRONTIERS IN PHARMACOLOGY (2021)
Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial
Masaomi Nangaku et al.
AMERICAN JOURNAL OF NEPHROLOGY (2021)
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
Ajay K. Singh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
Jose Portoles et al.
FRONTIERS IN MEDICINE (2021)
A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients
Yoshiharu Tsubakihara et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2020)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium
Lesley A. Inker et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease
Louis Holdstock et al.
CLINICAL KIDNEY JOURNAL (2019)
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
Amy M. Meadowcroft et al.
CLINICAL KIDNEY JOURNAL (2019)
Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease
Joshua M. Kaplan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Tadao Akizawa et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemias
Jennifer L. Ariazi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
Mai Sugahara et al.
KIDNEY INTERNATIONAL (2017)
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD
Nupur Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
The Dawning of a New Day in CKD Anemia Care?
Colin R. Lenihan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia
Louis Holdstock et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial
Richard A. Brigandi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis
Daniel Shepshelovich et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema
Stefano Fogli et al.
PHARMACOLOGICAL RESEARCH (2016)
Comparative Gene Expression Analysis of Two Mouse Models of Autism: Transcriptome Profiling of the BTBR and En2-/- Hippocampus
Giovanni Provenzano et al.
FRONTIERS IN NEUROSCIENCE (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients
Kimberly Zumbrennen-Bullough et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Effect of Food and Gemfibrozil on the Pharmacokinetics of the Novel Prolyl Hydroxylase Inhibitor GSK1278863
Brendan M. Johnson et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2014)
Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease
Peter A. McCullough et al.
AMERICAN JOURNAL OF NEPHROLOGY (2013)
Mechanisms of Anemia in CKD
Jodie L. Babitt et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Foreword
Bertram L. Kasiske et al.
KIDNEY INTERNATIONAL SUPPLEMENTS (2012)
The HIF Pathway and Erythrocytosis
Frank S. Lee et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Hepcidin Is Involved in Iron Regulation in the Ischemic Brain
Hui Ding et al.
PLOS ONE (2011)
Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia
Pinelopi P. Kapitsinou et al.
BLOOD (2010)
HIF-2α, but not HIF-1α, promotes iron absorption in mice
Maria Mastrogiannaki et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease
Nosratola D. Vaziri et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
PLOS MEDICINE (2009)
Correction of anemia with epoetin alfa in chronic kidney disease
Ajay K. Singh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Normalization of hemoglobin level in patients with chronic kidney disease and anemia
Tilman B. Drueke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
